Pharmosa Biopharm Inc. (TPEX: 6875)

Pharmosa Biopharm Cash Flow Statement

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-292.93	8.46	-266.51	-256.48	-181.7
Depreciation & Amortization	26.53	23.32	12.7	11.79	10.62
Other Amortization	-	-	-	0.01	-
Loss (Gain) on Equity Investments	-3.62	-5.5	-3.93	-0.66	-4.63
Stock-Based Compensation	3.5	0.87	0.59	15.04	4
Other Operating Activities	-4.56	-	-0.02	-0.02	-
Change in Accounts Receivable	-13.54	-1.18	0.03	-0.14	-0.15
Change in Inventory	-2.51	-21.91	-	-	-
Change in Accounts Payable	-8.31	0.59	-	2	-0.77
Change in Other Net Operating Assets	22.63	37.79	-1.19	-9.05	-8.83
Operating Cash Flow	-265.57	42.42	-258.31	-237.51	-181.45
Capital Expenditures	-189.27	-81.46	-10.16	-3.06	-7.05
Sale (Purchase) of Intangibles	-0.38	-0.01	-0.03	-0.19	-
Other Investing Activities	-6.78	-12.38	0.02	8	1.99
Investing Cash Flow	-1,065	-93.84	-10.17	4.75	-5.07
Short-Term Debt Issued	-	-	-	-	161
Long-Term Debt Issued	-	-	-	-	9.5
Total Debt Issued	-	-	-	-	170.5
Short-Term Debt Repaid	-	-	-	-61	-165
Long-Term Debt Repaid	-	-14.22	-15.9	-26.34	-33.99
Total Debt Repaid	-22.77	-14.22	-15.9	-87.34	-198.99
Net Debt Issued (Repaid)	-22.77	-14.22	-15.9	-87.34	-28.48
Issuance of Common Stock	965.99	367.18	495.42	367.02	637.29
Other Financing Activities	-2.73	-	-	-	-12
Financing Cash Flow	940.49	352.97	479.52	279.68	596.81
Foreign Exchange Rate Adjustments	0	0	0.01	-	-
Net Cash Flow	-390.52	301.55	211.05	46.93	410.29
Free Cash Flow	-454.84	-39.04	-268.47	-240.57	-188.5
Free Cash Flow Margin	-900.31%	-12.41%	-	-	-
Free Cash Flow Per Share	-3.68	-0.34	-2.72	-2.83	-3.96
Cash Interest Paid	2.86	2.86	0.65	1.21	3.86
Levered Free Cash Flow	-372.1	-50.37	-165.23	-135.95	-
Unlevered Free Cash Flow	-370.19	-48.59	-164.83	-135.19	-
Change in Net Working Capital	6.16	-10.46	-1.78	-3.17	-

Source: S&P Capital IQ. Standard template. Financial Sources.